Definition of miRNA Signatures of Nodal Metastasis in LCa: miR-449a Targets Notch Genes and Suppresses Cell Migration and Invasion.
Notch1
Notch2
invasion
laryngeal cancer
lymph nodes
metastases
miR-133b
miR-449a
microRNA
migration
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
05 Jun 2020
05 Jun 2020
Historique:
received:
04
02
2020
revised:
08
04
2020
accepted:
17
04
2020
pubmed:
14
5
2020
medline:
14
5
2020
entrez:
14
5
2020
Statut:
ppublish
Résumé
Laryngeal cancer (LCa), a neoplasm of the head and neck region, is a leading cause of death worldwide. Surgical intervention remains the mainstay of LCa treatment, but a crucial point is represented by the possible nodal involvement. Therefore, it is urgently needed to develop biomarkers and therapeutic tools able to drive treatment approaches for LCa. In this study, we investigated deregulated microRNAs (miRNAs) in tissues from LCa patients with either lymph node metastases (N+) or not (N-). miRNA expression profiling was performed by a comprehensive PCR array and subsequent validation by RT-qPCR. Results showed a significant decrease of miR-449a expression in N+ compared to N- patients, and miR-133b down-modulation in LCa tissues compared to paired normal ones. Receiver operating characteristic (ROC) curve analysis revealed the potential diagnostic power of miR-133b for LCa detection. According to the validation results, we selected miR-449a for further in vitro studies. Ectopic miR-449a expression in the LCa cell line Hep-2 inhibited invasion and motility in vitro, slowed cell proliferation, and induced the downregulation of Notch1 and Notch2 as direct targets of miR-449a. Collectively, this study provides new promising biomarkers for LCa diagnosis and a new opportunity to use miR-449a for the treatment of nodal metastases in LCa patients.
Identifiants
pubmed: 32402942
pii: S2162-2531(20)30114-1
doi: 10.1016/j.omtn.2020.04.006
pmc: PMC7218231
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
711-724Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
FASEB J. 2014 Dec;28(12):5097-110
pubmed: 25145628
J Surg Oncol. 2014 Oct;110(5):551-74
pubmed: 25053506
J Cell Physiol. 2009 Nov;221(2):412-23
pubmed: 19585524
Sci Rep. 2017 Sep 6;7(1):10696
pubmed: 28878284
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
pubmed: 16461460
Cell Physiol Biochem. 2018;46(6):2587-2600
pubmed: 29758550
PLoS One. 2011;6(12):e29094
pubmed: 22194996
Int J Cancer. 2010 Dec 15;127(12):2804-14
pubmed: 21351259
Mol Cancer. 2011 Mar 18;10:29
pubmed: 21418558
Mol Ther Nucleic Acids. 2014 Sep 23;3:e194
pubmed: 25247240
Oncotarget. 2012 Jan;3(1):9-21
pubmed: 22308266
Nat Rev Cancer. 2011 May;11(5):338-51
pubmed: 21508972
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
J Cell Physiol. 2013 Jan;228(1):130-41
pubmed: 22566192
Semin Cell Dev Biol. 2018 Jun;78:37-50
pubmed: 28765094
J Exp Med. 2011 Sep 26;208(10):1931-5
pubmed: 21948802
Oncotarget. 2016 Feb 16;7(7):8223-39
pubmed: 26882562
Laryngoscope. 1976 Jun;86(6):814-39
pubmed: 933673
J Hepatol. 2017 May;66(5):1012-1021
pubmed: 28088579
Nat Cell Biol. 2011 Jun;13(6):693-9
pubmed: 21602795
Oncol Rep. 2015 Dec;34(6):3111-9
pubmed: 26398771
Oncol Lett. 2016 Apr;11(4):2595-2598
pubmed: 27073523
J Cancer. 2015 Sep 15;6(11):1160-71
pubmed: 26516365
Br J Cancer. 2012 Jan 17;106(2):405-13
pubmed: 22068816
Cancer Cell. 2006 Mar;9(3):189-98
pubmed: 16530703
Mol Med Rep. 2016 Oct;14(4):3517-24
pubmed: 27572051
BMC Cancer. 2014 Jan 21;14:34
pubmed: 24443799
Cancer Lett. 2011 Aug 1;307(1):37-46
pubmed: 21481529
Clin Cancer Res. 2013 Apr 15;19(8):2187-96
pubmed: 23444217
Eur Arch Otorhinolaryngol. 2008 Oct;265(10):1245-55
pubmed: 18392632
PLoS One. 2013 May 29;8(5):e64759
pubmed: 23734217
BBA Clin. 2016 Nov 05;6:159-164
pubmed: 27896137
Oncotarget. 2015 Sep 15;6(27):23297-305
pubmed: 26079642
Oral Dis. 2015 Oct;21(7):850-7
pubmed: 25580884
Curr Drug Targets. 2016;18(1):35-55
pubmed: 27280795
Cell Death Differ. 2010 Mar;17(3):452-8
pubmed: 19960022
Science. 2005 Sep 2;309(5740):1519-24
pubmed: 16141061
Mol Ther. 2019 Feb 6;27(2):365-379
pubmed: 30341010
Oncotarget. 2010 Sep;1(5):349-58
pubmed: 20948989
Acta Otorhinolaryngol Ital. 2017 Dec;37(6):467-474
pubmed: 29327732
Head Neck. 2016 Apr;38 Suppl 1:E333-40
pubmed: 25581514
Nat Rev Genet. 2009 Oct;10(10):704-14
pubmed: 19763153
Cancer Treat Rev. 2006 Nov;32(7):504-15
pubmed: 16920269
Biochem Biophys Res Commun. 2009 Oct 23;388(3):483-9
pubmed: 19654003
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Cell Commun Signal. 2019 Jul 25;17(1):84
pubmed: 31345231
Cell Struct Funct. 2017;42(2):95-103
pubmed: 28768954
PLoS One. 2013 Aug 14;8(8):e71480
pubmed: 23967217
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6392-7
pubmed: 18427106
Cell. 2006 Nov 17;127(4):679-95
pubmed: 17110329
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087